- DexCom (DXCM -8.2%) sinks after the FDA approves Medtronic's (MDT +0.2%) MiniMed 530G.
- Billed as an "artificial pancreas," the device shuts down insulin delivery when it senses blood sugar levels have fallen too low.
- Both DXCM and Insulet (PODD -2.6%) could have done without the news — the companies market glucose monitors and insulin pumps.
Medtronic's MiniMed approval sinks DexCom, hits Insulet
Sep 27 2013, 13:57 ET